Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 12/20 | 0.58 |
| ▸ | MAOA | P21397 | 9/20 | 0.58 |
| ▸ | ACHE | P22303 | 1/20 | 0.56 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | CA4 | P22748 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15803972 | 0.88 | GSTP1 (0.61) | MAOBMAOAACHEGSTP1CA12 | |
| SCHEMBL20530610 | 0.83 | MAOB (0.62) | MAOBMAOAACHEGSTP1CA12 | |
| SCHEMBL30121657 | 0.81 | MAOB (0.59) | MAOBMAOAACHEGSTP1CA12 | |
| SCHEMBL2227926 | 0.81 | MAOB (0.59) | MAOBMAOAACHEGSTP1CA12 | |
| SCHEMBL536433 | 0.81 | MAOB (0.68) | MAOBMAOAACHEGSTP1CA12 | |
| SCHEMBL9155218 | 0.80 | GSTP1 (0.68) | MAOBMAOAACHEGSTP1CA12 | |
| SCHEMBL978718 | 0.78 | TP53 (0.65) | MAOACA12CA1CA2CA9 | |
| SCHEMBL126400 | 0.77 | CA12 (0.58) | MAOBMAOAACHEGSTP1CA12 | |
| SCHEMBL20540823 | 0.76 | MAOB (0.69) | MAOBMAOAGSTP1 | |
| SCHEMBL1271679 | 0.75 | MAOA (0.64) | MAOBMAOACA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11117873-B2 | Oxazine compound, composition, and cured product | DIC CORPORATION (JP) | 2021-09-14 | — | — | US | disclosed |
| US-11028059-B2 | Oxazine compound, composition and cured product | DIC CORPORATION (JP) | 2021-06-08 | — | — | US | disclosed |
| US-20180362480-A1 | OXAZINE COMPOUND, COMPOSITION, AND CURED PRODUCT | DIC CORPORATION (JP) | 2018-12-20 | — | — | US | disclosed |
| US-20180362477-A1 | OXAZINE COMPOUND, COMPOSITION AND CURED PRODUCT | DIC CORPORATION (JP) | 2018-12-20 | — | — | US | disclosed |
| EP-3388461-A1 | OXAZINE COMPOUND, COMPOSITION, AND CURED PRODUCT | DIC Corporation (JP) | 2018-10-17 | — | — | EP | disclosed |
| EP-3388459-A1 | OXAZINE COMPOUND, COMPOSITION AND CURED PRODUCT | DIC Corporation (JP) | 2018-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11028059-B2 | Oxazine compound, composition and cured product | KDM5A, WDR5, RNF5 | MAOB 1747/4885MAOA 1166/4885ACHE 1217/4885 |
| US-20180362480-A1 | OXAZINE COMPOUND, COMPOSITION, AND CURED PRODUCT | KDM5A, WDR5, SMC4 | MAOB 1509/4885MAOA 894/4885ACHE 856/4885 |
| US-11117873-B2 | Oxazine compound, composition, and cured product | KDM5A, WDR5, SMC4 | MAOB 1509/4885MAOA 894/4885ACHE 856/4885 |
| US-20180362477-A1 | OXAZINE COMPOUND, COMPOSITION AND CURED PRODUCT | KDM5A, WDR5, RNF5 | MAOB 1747/4885MAOA 1166/4885ACHE 1217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.